As the Senate prepares to vote on a reconciliation bill as soon as this weekend, KFF has several recent analyses relevant to understanding the health provisions in the sweeping $740 billion legislation, as well as their potential impact on people.
The legislation would lower prescription drug costs for people with Medicare and private insurance and reduce drug spending by the federal government. Most notably, it would require the U.S. Secretary of Health and Human Services to negotiate drug prices for people on Medicare, require drug companies to pay a rebate to the government if drug prices rise faster than inflation for Medicare and private insurance, and cap out-of-pocket drug spending for people with Medicare – all proposals with broad public support.
The bill also would extend for three years the enhanced Affordable Care Act subsidies that Congress passed last year as part of the American Rescue Plan Act. That temporary boost increased the amount of financial help available to people already eligible to buy subsidized health plans in the ACA Marketplaces, and expanded subsidies to more middle-income people, many of whom were previously priced out of coverage.
Medicare prescription drug provisions